Reuters logo
BRIEF-Abbvie says investigational IL-23 inhibitor Risankizumab receives Orphan Drug Designation from U.S. FDA
November 30, 2016 / 7:05 PM / a year ago

BRIEF-Abbvie says investigational IL-23 inhibitor Risankizumab receives Orphan Drug Designation from U.S. FDA

Nov 30 (Reuters) - Abbvie Inc :

* Abbvie receives Orphan Drug Designation for investigational IL-23 inhibitor Risankizumab from the U.S. Food and Drug Administration for the treatment of pediatric patients with Crohn’s Disease Source text for Eikon: Further company coverage:

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below